Ask anyone involved with antibody drug conjugates (ADCs), and they will tell you this is an exciting time to be in the market. While there are some concerns about possible regulatory guidance that will eventually be crafted to address this relatively new market, two recent FDA approvals (Adcetris and Kadcyla), and several more products in clinical trials has the future looking bright. Partnerships, such as the ones between Seattle Genetics and Spirogen, Celgene and Sutro Biopharma, and the acquisition of MedImmune by AstraZeneca, have been instrumental in advancing ADCs, and will continue to drive the technology going forward.